Inside Moderna and Merck’s cancer vaccine triumph

Live updates

1. 19d ago

   Moderna and Merck's cancer vaccine shows promise

   Moderna and Merck's cancer vaccine, using mRNA technology, has shown effectiveness in reducing melanoma recurrence risk in a late-stage trial, leading to increased investor confidence.

   Why it matters

   The vaccine's success could mark a significant advancement in cancer treatment, offering new hope for patients. The trial's positive results have already impacted Moderna's stock price. This development is part of a broader effort to explore mRNA technology in fighting cancer.

   What is confirmed

   • Moderna and Merck's cancer vaccine uses mRNA technology.
   • The vaccine has shown effectiveness in reducing melanoma recurrence risk in a late-stage trial.

   What to watch next

   • Further trial results and FDA approval process
   • Moderna and Merck's plans for vaccine commercialization
   • Comparative studies with other cancer treatments
   Sources used for this update (6)

   1. The Economist — It now seems possible to vaccinate against cancer
   2. jen.jiji.com — Voodoo doll with asbestos, Ministry of Health issues warning: "Dangerous if broken"
   3. jen.jiji.com — Trump and the 'Economic D-Day' against Iran, does the latest US offensive depend on China?
   4. www.statnews.com — Sword Health to acquire Headspace, according to filing
   5. www.statnews.com — What’s in Merck and Moderna’s cancer vaccine algorithm?
   6. www.statnews.com — CMS plans launch event for ACCESS, the Medicare chronic care pilot
   confidence 100%
2. 21d ago

   Moderna and Merck's cancer vaccine shows promise in late-stage trial

   Moderna and Merck's cancer vaccine, tested in a late-stage trial, has shown promise in preventing melanoma from returning. The vaccine, which uses mRNA technology, has been found to be effective in reducing the risk of cancer recurrence. The trial's positive results have led to a significant increase in Moderna's stock price.

   Why it matters

   The development of a cancer vaccine has been a long-standing goal in the medical community, and the success of this trial could pave the way for new treatments and potentially even preventative measures against certain types of cancer. The use of mRNA technology in vaccine development has gained significant attention in recent years, particularly in the context of COVID-19 vaccines.

   What is confirmed

   • Moderna and Merck's cancer vaccine shows promise in preventing melanoma from returning
   • The vaccine uses mRNA technology
   • The trial's positive results have led to a significant increase in Moderna's stock price

   What to watch next

   • Further trial results and data analysis
   • Regulatory approval and potential market release
   • Impact on current cancer treatment options and patient outcomes
   Sources used for this update (12)

   1. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
   2. The New York Times — Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
   3. Reuters — Moderna, Merck breakthrough could usher in wave of cancer vaccines
   4. WSJ — Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math
   5. The Washington Post — What it was like to go through a trial that could revolutionize cancer treatment
   6. STAT — Inside Moderna and Merck’s cancer vaccine triumph
   7. WPR — Wisconsin doctor responds to ‘breakthrough trial’ of new cancer vaccine
   8. CNN — Cancer vaccines could transform treatment and prevention – but misinformation about mRNA vaccines threatens their potential
   9. Barron's — What Moderna Must Do to Take Its Stock to the Next Level
   10. BBC — Will the new cancer vaccine survive RFK Jr’s America?
   11. finance.yahoo.com — Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.
   12. www.usatoday.com — Moderna's personalized cancer vaccine shows promise. Here's why
   confidence 85%